^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | NSC23766 (RAC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NPM1 MUTATED SAMPLES ARE ESPECIALLY VULNERABLE WHEN TARGETING RAC1 IN PATIENT-DERIVED AML CELLS IN VITRO
Published date:
05/12/2022
Excerpt:
We aimed to map the antileukemic effect in a relatively large AML cohort...For NSC23766 only, the presence of NPM1 mutation was associated with more severe apoptosis and necrosis (p=0.01)….Presence of NPM1 mutation was associated with reduced viability after treatment with EHOP-16 (p=0.025), ITX3 (p=0.047) and NSC23766 (p=0.005).
